Cargando…

Human Platelets Take up Anti-VEGF Agents

PURPOSE: Growing evidence suggests different systemic exposure of anti-vascular endothelial growth factor (anti-VEGF) agents with repeated intravitreal application. Since the penetration of anti-VEGF agents through vascular barrier was reported, the interaction of anti-VEGF with nonresident platelet...

Descripción completa

Detalles Bibliográficos
Autores principales: Sobolewska, B., Fehrenbacher, B., Münzer, P., Kalbacher, H., Geue, S., Stellos, Konstantinos, Schaller, M., Ziemssen, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219439/
https://www.ncbi.nlm.nih.gov/pubmed/34221496
http://dx.doi.org/10.1155/2021/8811672
_version_ 1783710927576629248
author Sobolewska, B.
Fehrenbacher, B.
Münzer, P.
Kalbacher, H.
Geue, S.
Stellos, Konstantinos
Schaller, M.
Ziemssen, F.
author_facet Sobolewska, B.
Fehrenbacher, B.
Münzer, P.
Kalbacher, H.
Geue, S.
Stellos, Konstantinos
Schaller, M.
Ziemssen, F.
author_sort Sobolewska, B.
collection PubMed
description PURPOSE: Growing evidence suggests different systemic exposure of anti-vascular endothelial growth factor (anti-VEGF) agents with repeated intravitreal application. Since the penetration of anti-VEGF agents through vascular barrier was reported, the interaction of anti-VEGF with nonresident platelets has become a topic of interest. The purpose of this study was to evaluate, with the help of visualization techniques, whether platelets take up the anti-VEGF agents ranibizumab, aflibercept, and bevacizumab. METHODS: The uptake of anti-VEGF agents with or without VEGF treatment was investigated using immunofluorescence and immunogold staining in human platelets. The role of actin filaments and clathrin-coated vesicles in the transport of ranibizumab, aflibercept, and bevacizumab was evaluated by two pharmacologic inhibitors: staurosporine (protein kinase C inhibitor) and cytochalasin D. RESULTS: All three anti-VEGF agents were taken up by platelets and colocalized with VEGF. Ranibizumab and aflibercept were mainly detected in alpha-granules; however, bevacizumab was equally localized in alpha-granules and in platelet vesicles. Both staurosporine and cytochalasin D completely inhibited the uptake of aflibercept into platelets. Both pharmacological inhibitors also decreased the transport of ranibizumab and bevacizumab into platelets. Bevacizumab was significantly more frequently colocalized within clathrin-coated vesicles than ranibizumab and aflibercept. CONCLUSION: All three anti-VEGF agents are taken up by platelets and internalized in alpha-granules, which may result in a higher local exposure of anti-VEGF after the activation of platelets, potentially contributing to arterial thromboembolic events. Clathrin-coated vesicles seem to be more prominent in the transport of bevacizumab than ranibizumab and aflibercept. Nevertheless, whether the different localization and transport of bevacizumab are truly related to specific differences of receptor-mediated endocytosis has to be revealed by further research.
format Online
Article
Text
id pubmed-8219439
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-82194392021-07-02 Human Platelets Take up Anti-VEGF Agents Sobolewska, B. Fehrenbacher, B. Münzer, P. Kalbacher, H. Geue, S. Stellos, Konstantinos Schaller, M. Ziemssen, F. J Ophthalmol Research Article PURPOSE: Growing evidence suggests different systemic exposure of anti-vascular endothelial growth factor (anti-VEGF) agents with repeated intravitreal application. Since the penetration of anti-VEGF agents through vascular barrier was reported, the interaction of anti-VEGF with nonresident platelets has become a topic of interest. The purpose of this study was to evaluate, with the help of visualization techniques, whether platelets take up the anti-VEGF agents ranibizumab, aflibercept, and bevacizumab. METHODS: The uptake of anti-VEGF agents with or without VEGF treatment was investigated using immunofluorescence and immunogold staining in human platelets. The role of actin filaments and clathrin-coated vesicles in the transport of ranibizumab, aflibercept, and bevacizumab was evaluated by two pharmacologic inhibitors: staurosporine (protein kinase C inhibitor) and cytochalasin D. RESULTS: All three anti-VEGF agents were taken up by platelets and colocalized with VEGF. Ranibizumab and aflibercept were mainly detected in alpha-granules; however, bevacizumab was equally localized in alpha-granules and in platelet vesicles. Both staurosporine and cytochalasin D completely inhibited the uptake of aflibercept into platelets. Both pharmacological inhibitors also decreased the transport of ranibizumab and bevacizumab into platelets. Bevacizumab was significantly more frequently colocalized within clathrin-coated vesicles than ranibizumab and aflibercept. CONCLUSION: All three anti-VEGF agents are taken up by platelets and internalized in alpha-granules, which may result in a higher local exposure of anti-VEGF after the activation of platelets, potentially contributing to arterial thromboembolic events. Clathrin-coated vesicles seem to be more prominent in the transport of bevacizumab than ranibizumab and aflibercept. Nevertheless, whether the different localization and transport of bevacizumab are truly related to specific differences of receptor-mediated endocytosis has to be revealed by further research. Hindawi 2021-06-14 /pmc/articles/PMC8219439/ /pubmed/34221496 http://dx.doi.org/10.1155/2021/8811672 Text en Copyright © 2021 B. Sobolewska et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Sobolewska, B.
Fehrenbacher, B.
Münzer, P.
Kalbacher, H.
Geue, S.
Stellos, Konstantinos
Schaller, M.
Ziemssen, F.
Human Platelets Take up Anti-VEGF Agents
title Human Platelets Take up Anti-VEGF Agents
title_full Human Platelets Take up Anti-VEGF Agents
title_fullStr Human Platelets Take up Anti-VEGF Agents
title_full_unstemmed Human Platelets Take up Anti-VEGF Agents
title_short Human Platelets Take up Anti-VEGF Agents
title_sort human platelets take up anti-vegf agents
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219439/
https://www.ncbi.nlm.nih.gov/pubmed/34221496
http://dx.doi.org/10.1155/2021/8811672
work_keys_str_mv AT sobolewskab humanplateletstakeupantivegfagents
AT fehrenbacherb humanplateletstakeupantivegfagents
AT munzerp humanplateletstakeupantivegfagents
AT kalbacherh humanplateletstakeupantivegfagents
AT geues humanplateletstakeupantivegfagents
AT stelloskonstantinos humanplateletstakeupantivegfagents
AT schallerm humanplateletstakeupantivegfagents
AT ziemssenf humanplateletstakeupantivegfagents